AUTHORS
Roberta S. Santos Azevedo, MD, Omer Karrar, MD2, Guillermo Montalban-Bravo, MD3, Guillermo Garcia-Manero, MD4, Wei Ying Jen, BM BCh, FRCPath5, Alexandre Bazinet, MD, MSc6, Ghayas C. Issa, MD7, Alex Bataller, MD, PhD8, Gautam Borthakur, MD9, Courtney DiNardo, MD, MSCE10, Naval Daver, MD11, Tapan Kadia I, MD12, Sankalp Arora, MD13, Prithviraj Bose, MD14, Kelly Sharon Chien, MD15, Abhishek Maiti, MBBS16, Maro Ohanian, DO17, Christopher Loiselle, BS18, Regina Abramova19, Farhad Ravandi, MD20, Hussein Ali Abbas, MD, PhD21, Nicholas Short, MD22
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
22 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: Primary resistance and relapse are major clinical challenges in patients (pts) with high-risk (HR) acute myeloid leukemia (AML). Outcomes remain particularly poor among pts with TP53 mutations (TP53mut) and those with “treated secondary AML” (ts-AML; i.e., those who received prior AML-like therapy for an antecedent myeloid malignancy). Venetoclax (VEN) and gilteritinib (GILT) are synergistic in preclinical models of HR FLT3 wild-type (WT) AML (Janssen M, et al. Blood, 2022). Therefore, we evaluated the safety and efficacy of azacitidine (AZA), VEN, and GILT in pts with HR AML.
Methods: This phase II study enrolled adults with newly diagnosed FLT3-WT AML who had adverse-risk disease according to ELN 2022 and/or ts-AML (irrespective of cytomolecular risk). During cycle 1, pts received AZA 75 mg/m² on days 1–7, VEN 400 mg (target dose after ramp-up) on days 1–28, and GILT 80 mg on days 1–14. Bone marrow was assessed on day 14; VEN was held if blasts were <5% or aplastic/inadequate marrow. For cycle 2 and beyond, AZA and VEN were given on days 1–7, and GILT on days 1–14 at the same doses. The primary endpoint was the composite complete remission (CRc) rate, defined as CR + CRi. Secondary endpoints included CR rate, measurable residual disease (MRD) negativity rate by flow cytometry, relapse-free survival (RFS), overall survival (OS), stem cell transplantation (SCT) rate, and safety. Astellas Pharma provided GILT drug support for this study.
Results: From August 2024 to May 2026, 32 pts were enrolled. Median age was 71 years (range, 45–86). 18 pts (56%) had an antecedent myeloid disorder (MDS, n=15 and MPN, n=3). 13 pts (41%) had ts-AML, including 10 with prior hypomethylating agent (HMA) exposure and 1 with prior HMA + VEN. All but one pt had adverse-risk disease according to ELN 2022. 18 of 29 pts (62%) with available cytogenetic data had an adverse karyotype. 15 pts (47%) had TP53mut, all of which were biallelic, with a median TP53 VAF of 52% (range, 17–82%). 2 pts (6%) had a MECOMr. Myelodysplasia-related gene mutations occurred in 14 pts (44%); the most frequent were RUNX1 (25%), BCOR (16%), SF3B1 (16%), and STAG2 (13%).
The CRc rate was 50%, including a CR rate of 28%. 4 additional pts achieved a morphologic leukemia-free state, for an overall response rate of 63%. 10 pts (31%) did not respond, and 2 (6%) died early and were not evaluable for response. The CRc rate was 40% (6/15) in pts with TP53mut, 38% (5/13) in pts with ts-AML, and 75% (6/8) in patients with neither. At best response, 10/20 responders (50%) achieved MRD negativity, including 4 responding pts (57%) with TP53mut and 2 (29%) with ts-AML.
At study enrollment, 19 pts (59%) were considered candidates for SCT; 8 (42%) underwent SCT after a median of 3.7 months (range, 2.9–6.6). The main reason for not proceeding to SCT was lack of response (n=5), while 2 pts are in ongoing remission and planned for SCT.
After a median follow-up of 10 months (95% CI, 4–14), 4 of the 20 responding pts (20%) relapsed: 3 who had not undergone SCT and 1 following SCT, with a median time from remission to relapse of 3 months (range, 2–19). The median RFS was 19 months (95% CI, 10–not reached [NR]), and the median OS was 11 months (95% CI, 6–NR). Among responding pts with TP53mut AML and ts-AML, the median RFS was 19 months (95% CI, NE-NR) and 10 months (95% CI, 5-NR), respectively. The median RFS was NR (95% CI, NR-NR) for those with neither TP53-mutated nor ts-AML.
Pts received a median of 2 cycles of therapy (range, 1–8). The most common grade ≥3 nonhematologic adverse events were febrile neutropenia (34%), lung infection (22%), and hypertension and sepsis (19% each). The 30- and 60-day mortality rates were 9% and 13%, respectively. Among responders, the median time to neutrophil (≥1.0×10⁹/L) and platelet recovery (≥100×10⁹/L) was 39 days and 23 days, respectively, after cycle 1. Among the 13 pts who received ≥2 cycles and achieved remission by end of cycle 1, 4 (31%) required a dose reduction: AZA in 3 pts (23%), and GILT in 1 (8%).
Conclusion: AZA, VEN, and GILT demonstrated promising remission durations in pts with HR FLT3-WT AML, including TP53mut- and ts-AML; however, OS remains suboptimal. The study continues to accrue pts, and single-cell RNA profiling of paired baseline and response samples is ongoing and may provide insights into which pt subsets are most likely to benefit from GILT-based therapy.
DISCLOSURES
Nicholas Short, MD: Sanofi - Honoraria; Astellas Pharma Inc - Honoraria; Pfizer Inc - Honoraria; BeiGene - Honoraria; AstraZeneca - Honoraria; Novartis - Honoraria; Amgen - Honoraria; Takeda - Honoraria; Merck - Honoraria; Adaptive Biotechnologies - Honoraria; Xencor - Research Funding; Hemogenyx - Research Funding; Astellas Pharma Inc - Research Funding; Takeda - Research Funding; Nexcure - Research Funding; Remedy Plan - Research Funding; NextCure - Research Funding; Vironexis - Research Funding; Takeda Oncology - Research Funding; GSK - Research Funding; Stemline Therapeutics - Research Funding; Novartis - Research Funding; Ascentage - Research Funding; Honoraria - Research Funding; Pfizer Inc - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); AB Science - Consultancy (Includes expert testimony); NKARTA - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Merck - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony)